Evidence map›Paper›PMID 40877362›Full record

ArticleScientific reports2025

Impacts of immune checkpoint inhibitors use on the HIV reservoir are linked to provirus sequences but not integration sites.

Vincent Guiraud, Antoine Fauchois, Cathia Soulie, Valentin Leducq, Marianne Veyri, Lambert Assoumou, David Boutolleau, Dominique Costagliola, Olivier Lambotte, Jean-Philippe Spano and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Vincent GuiraudSorbonne University, INSERM, Pierre Louis Institute of Epidemiology and Public Health, AP-HP, Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix, Laboratoire de Virologie, Paris, 75013, France. vincent.guiraud@aphp.fr.
Antoine FauchoisSorbonne University, INSERM, Pierre Louis Institute of Epidemiology and Public Health, AP-HP, Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix, Laboratoire de Virologie, Paris, 75013, France.
Cathia SoulieSorbonne University, INSERM, Pierre Louis Institute of Epidemiology and Public Health, AP-HP, Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix, Laboratoire de Virologie, Paris, 75013, France.
Valentin LeducqSorbonne University, INSERM, Pierre Louis Institute of Epidemiology and Public Health, AP-HP, Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix, Laboratoire de Virologie, Paris, 75013, France.
Marianne VeyriSorbonne University, INSERM, Pierre Louis Institute of Epidemiology and Public Health (IPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Service d'Oncologie Médicale, Paris, 75013, France.
Lambert AssoumouSorbonne University, INSERM, Pierre Louis Institute of Epidemiology and Public Health, Paris, France.
David BoutolleauSorbonne University, INSERM, Pierre Louis Institute of Epidemiology and Public Health, AP-HP, Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix, Laboratoire de Virologie, Paris, 75013, France.
Dominique CostagliolaSorbonne University, INSERM, Pierre Louis Institute of Epidemiology and Public Health, Paris, France.
Olivier LambotteService de Médecine Interne et Immunologie Clinique, Hôpital Bicêtre, Faculté de Médecine Paris Saclay, Assistance publique-Hôpitaux de Paris, Paris Saclay University, Le Kremlin-Bicêtre cedex, 94275, France.
Jean-Philippe SpanoDepartment of Medical Oncology, Pitié Salpêtrière Hospital, AP-HP, Pierre Louis Institute of Epidemiology and Public Health (iPLESP), INSERM, Sorbonne University, Paris, France.
Valérie PourcherService des Maladies Infectieuses et Tropicales, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France.
Anne-Geneviève MarcelinSorbonne University, INSERM, Pierre Louis Institute of Epidemiology and Public Health, AP-HP, Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix, Laboratoire de Virologie, Paris, 75013, France.
Vincent CalvezSorbonne University, INSERM, Pierre Louis Institute of Epidemiology and Public Health, AP-HP, Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix, Laboratoire de Virologie, Paris, 75013, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibodies to programmed cell death 1 (PD-1), Programmed death-ligand 1 (PDL-1) and Cytotoxic-T-lymphocyte-associated protein 4 (CTLA-4) can revert HIV latency and enhance anti-HIV cytotoxic response but their impact on HIV proviral sequences and integration landscape in people with HIV (PWH) remain to be studied. Two PWH treated with PD-1/PDL-1 and one with PD-1/CTLA4 were studied among the ANRS-CO-24 OncoVIHAC cohort study. Matched integration site and proviral sequencing were performed pre- and post-treatment. Immune checkpoint inhibitors (ICI) were not associated with significant changes in total cell-associated HIV-DNA, nor significant changes in genomic or epigenetic features of integration sites. ICIs were associated with a lesser proportion of proviruses with pol frameshifts for all regimen, with the PD-1 and PD-1/CTLA4 patients also experiencing a higher proportion of proviral sequences harboring gag frameshifts and a higher number of STOP codons, consistent with a gag-driven immune clearance. ICI use were also associated with a limited reduction in the HIV-reservoir diversity. Finally, the patient with a PD-1/CTLA4 treatment exhibited the loss of an HIV-clone in the NIN-oncogene representing 17% of all his pre-treatment sequences. Despite stable levels of cell-associated HIV DNA, ICI treatment can lead to modest changes in proviral sequences landscapes.

Indexed as

HIV-1HIV InfectionsImmune Checkpoint InhibitorsProvirusesVirus IntegrationB7-H1 AntigenCTLA-4 AntigenDNA, ViralFemaleHumansMaleMiddle AgedProgrammed Cell Death 1 ReceptorVirus LatencyB7-H1 AntigenCTLA-4 AntigenDNA, ViralImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorCTLA-4HIV cureIntegration siteMIP-SeqPD-1Shock and killViral reservoir

Identifiers

PMID40877362
PMCPMC12394651

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.